Lipella Pharmaceuticals (LIPO) shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.
Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.
TransCode Therapeutics (RNAZ) said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.
Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.
Tapestry (TPR) reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.
Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.
Price: 4.69, Change: +2.07, Percent Change: +79.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.